Kiniksa Pharmaceuticals, Ltd. (KNSA) - Stock Analysis
Last updated: Jun 8, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q1 2026 beat expectations with EPS of $0.27 vs. $0.18 expected, ARCALYST revenue rose 56% YoY to $214.3M, 2026 ARCALYST revenue guidance was raised to $930M-$945M, and the stock is trading near 52-week highs.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High Margins ⢠Net Cash ⢠SBC Dilution KNSA posted strong margins, solid cash flow, and a net cash balance sheet, but the shares look expensive and past losses plus stock-based dilution remain risks.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support holding ⢠Resistance overhead Support Level: $46.92-$47.00 Resistance Level: $50.84 Over the last month, KNSA has slipped into a short-term downtrend with lower highs and lows, and while $46.92 support sparked a modest bounce, resistance at $50.84 and $52.86-$54.28 is still capping recovery.
Sentiment & News
Key News Insights: ⢠Share weakness ⢠GF Value ⢠Investor conferences Kiniksa Pharmaceuticals fell 4.8% to near its GF Value while management highlighted upcoming investor conference chats, signaling weak share momentum and steady investor outreach.
AI Summary
KNSA has shifted from a speculative biotech into a commercially validated, cash-generative Arcalyst story with strong revenue growth and margins, but with the stock already priced for success, the key investment risk is whether it can sustain this momentum without a second growth engine or a valuation reset.
Description
Kiniksa Pharmaceuticals is a biopharmaceutical company that discovers, acquires, develops and commercializes therapies for patients with serious conditions lacking adequate treatment options. Its portfolio includes an approved interleukin-1 therapy for recurrent pericarditis and several monoclonal antibody candidates in clinical development for inflammatory and immune-mediated diseases. The company was incorporated in 2015 and is headquartered in Hamilton, Bermuda.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 29 | May 6 | KNSA | Kiniksa Pharmaceuticals, Ltd. | Q1 2026 beat expectations with EPS of $0.27 vs. $0.18 expected, ARCALYST revenue rose 56% YoY to $214.3M, 2026 ARCALYST revenue guidance was raised to $930M-$945M, and the stock is trading near 52-week highs. | Closed | +9.9% |